ABSTRACT Escherichia coli can colonize the urinary bladder without causing a disease response in the host. This asymptomatic bacteriuria (ABU) can protect against recurrent symptomatic urinary tract infection by virulent bacteria. Here, we report the whole-genome sequences of nine E. coli ABU isolates from diabetic patients.
U
rinary tract infection (UTI) constitutes a serious global health problem associated with considerable morbidity and death and can affect patient quality of life. Symptomatic UTI is caused most often by Escherichia coli. Besides provoking symptoms, E. coli can also asymptomatically colonize the human bladder for extended time periods. Asymptomatic bacteriuria (ABU) does not, with some exceptions, require any treatment (1) . Deliberate colonization of the urinary bladder thus represents a promising alternative to antibiotic treatment and prevents colonization by more virulent bacterial strains (2) (3) (4) . To characterize bacterial traits that contribute to the fitness and competitiveness of E. coli ABU strains in urine, we sequenced nine ABU isolates from patients with diabetes mellitus in Hungary.
Total genomic DNA was isolated from the E. coli ABU isolates using the MagAttract high-molecular-weight (HMW) DNA kit (Qiagen, Hilden, Germany). To prepare 500-bp paired-end libraries of all ABU isolates, we used the Nextera XT DNA library preparation kit (Illumina, San Diego, CA, USA). Libraries were sequenced on the Illumina MiSeq sequencing platform using v2 sequencing chemistry. E. coli ABU isolate 65 was sequenced twice on the Illumina platform. In addition, this strain was subjected to whole-genome bidirectional sequencing using the Roche GS Junior sequencer with titanium chemistry (Roche Hungary Ltd., Budaörs, Hungary). E. coli ABU strain 65 reads from the Illumina and Roche sequencing platforms were included in a hybrid assembly. Prior to assembly, raw reads of all ABU isolates were quality checked with FastQC (v11.5) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc), and low-quality reads were trimmed using Sickle (v1.33) (https://github.com/najoshi/sickle). Subsequently, the quality-filtered reads were de novo assembled using SPAdes (v3.9.0) (5). Final genome assemblies were analyzed using QUAST (v4.3) (6), resulting in 43 to 197 contigs of Ͼ1 kb, and accounting for total genome sizes ranging from 4,578,015 to 5,285,335 bp (Table 1) . Coding sequences (CDSs) and orthologous genes were determined using Prokka (v1.12) (7) and Proteinortho (v5.15) (8) . Between 4,204 and 5,035 coding DNA sequences were identified in the corresponding genomes (Table 1) . To predict and identify plasmids, serotypes, and acquired antibiotic resistance mechanisms, we performed a systematic analysis, querying the databases PlasmidFinder (v1.3) (9), SerotypeFinder (v1.1) (10), and ResFinder (v2.1) (11), respectively. For the determination of virulence factors (VFs), we extended the freely available E. coli VF collection (v0.1) (https://doi.org/10.5281/zenodo.56686). Core genome multilocus sequence typing (cgMLST) was performed with SeqSphere ϩ (v3.4.0) (Ridom GmbH, Münster, Germany).
The draft genomes of nine clinical ABU isolates from diabetic patients will serve as a useful source for upcoming comparative studies of E. coli isolate virulence-and fitness-related traits that promote efficient growth and competitiveness in urine. The identification of bacterial characteristics relevant for efficient and safe therapeutic bladder colonization will improve the application of bacterial interference.
Accession number(s).
The assembled draft genome sequences obtained from this project were deposited into DDBJ/ENA/GenBank under the accession numbers listed in Table 1 .
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